The private equity-backed anesthesia provider bought and bullied its way to market dominance in Texas, driving up prices for patients, the FTC alleged. The parties have now reached a deal, though USAP will not admit liability.
The report compiled by Sen. Maria Cantwell, D-Wash., found procedures in the state that were previously approved within around two weeks now take four to eight weeks to be authorized.
The pathway is designed to reduce the delay between FDA authorization and Medicare coverage for certain Class II and Class III breakthrough medical devices.
The insurer beat analyst expectations for adjusted earnings in the first quarter. But steeper Medicaid membership losses than expected could saddle Molina with higher costs down the line.
Executives said consumer fears and aggressive denials from payers fueled declining volumes in the quarter, which led CHS to a $58 million loss. Still, the hospital operator said it expects volumes to pick up in the back half of the year.
Though chatbots could have some benefits for mental health access, the physician lobby argued “immediate attention is required” to avoid harming patients looking for support.
The data, compiled by the Brookings Center on Health Policy, shows that average prices for some services like imaging were seven-times higher than Medicare prices.
The company argues the offering is a more comprehensive approach to weight management, allowing patients to receive ongoing support care and transparent pricing on prescriptions.
The Indianapolis-based insurer raised its 2026 earnings guidance after posting a better first quarter than Wall Street expected. Still, Elevance expects it’ll have to pay the CMS around $935 million this year due to faulty MA data reporting.
A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.